 CAMBRIDGE, Mass., March 15, 2021 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. Nasdaq: MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced the publication of two manuscripts in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research AACR. The manuscripts describe the preclinical development of the Dolaflexin ADC platform and XMT-1536, now called upifitamab rilsodotin UpRi, Mersanas first-in-class NaPi2b-targeted ADC developed using this platform. 